...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of orthopaedic research >Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777
【24h】

Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777

机译：Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

ABSTRACT Osteosarcoma (OSA) is the most common primary bone malignancy overall and is responsible for considerable adolescent mortality. Approximately 850 patients are newly diagnosed with OSA in the United States each year. While the 5‐year survival rate for localized OSA has improved from <20% over 40 years ago to over 65% today, progress has dwindled over the past three decades. Therapeutic stagnation has occurred, in part, as a result of limited preclinical models and the overall heterogeneity of OSA among patients. In this study, we report the establishment and characterization of a novel OSA cell line: OSA 1777. This cell line was isolated from the recurrent tumor specimen of a 19‐year‐old female who initially experienced 99% tumor necrosis after neoadjuvant chemotherapy and eventually had local recurrence and metastases. We present OSA 1777 growth characteristics, tumor markers, chemotherapeutic sensitivities, and oncogenic spheroid formation. In a two‐dimensional (2D) monolayer culture, OSA 1777 exhibited a spindle shape and 60?h doubling time. STR DNA profiling revealed a unique genomic identity not matching any existing human cancer cell lines from the ATCC or DSMZ databases. Consistent with the mesenchymal origin, western blot was positive for vimentin and negative for the carcinoma marker cytokeratin. Within three‐dimensional (3D) culture, the cells formed spheroids of similar patterning and smaller size compared with MNNG‐HOS and U2OS cell lines. The chemotherapeutic drug sensitivity of OSA 1777 was evaluated in both 2D and 3D culture systems. In summary, we report OSA 1777 as a novel biological model of OSA amenable to future studies focused on OSA that recurs despite an initially strong chemotherapeutic response. ? 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:902‐910, 2020

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号